Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.109.154997PMID 19741151PMCID PMC2784710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell cycle kinases as therapeutic targets for cancer

  2009cited by this paper
• Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response*

  2009cited by this paper
• BRCA1 is regulated by Chk2 in response to spindle damage.

  2008cited by this paper
• The DNA Damage Sensors Ataxia-Telangiectasia Mutated Kinase and Checkpoint Kinase 2 Are Required for Hepatitis C Virus RNA Replication

  2008cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008influential reference
• Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.

  2008cited by this paper
• Death Receptor-Induced Activation of the Chk2- and Histone H2AX-Associated DNA Damage Response Pathways

  2008cited by this paper
• Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor

  2008cited by this paper
• DNA damage induces two distinct modes of cell death in ovarian carcinomas

  2008cited by this paper
• Identification of a Bis-guanylhydrazone [4,4′-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a Novel Chemotype for Inhibition of Chk2 Kinase

  2007influential reference
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?

  2007cited by this paper
• Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2

  2007cited by this paper
• Identification of novel, selective and potent Chk2 inhibitors.

  2007cited by this paper
• Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage

  2006influential reference
• Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors

  2006cited by this paper
• Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange

  2006cited by this paper
• Activated checkpoint kinase 2 provides a survival signal for tumor cells.

  2006cited by this paper
• Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase

  2005cited by this paper
• Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

  2005cited by this paper
• DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

  2005cited by this paper
• Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles.

  2005cited by this paper
• Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.

  2005cited by this paper
• Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine.

  2004cited by this paper
• The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe

  2004cited by this paper
• Autophosphorylation of Checkpoint Kinase 2 at Serine 516 Is Required for Radiation-induced Apoptosis*

  2003influential reference
• Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription

  2002cited by this paper
• Checkpoint Kinase 2 (Chk2) Monomers or Dimers Phosphorylate Cdc25C after DNA Damage Regardless of Threonine 68 Phosphorylation*

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.

  2002cited by this paper
• Structural biology in drug design: selective protein kinase inhibitors.

  2002cited by this paper
• Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway

  2001cited by this paper
• Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage‐induced S and G2 checkpoints and enhances apoptotic activity in HEK‐293 cells

  2001cited by this paper
• Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine*

  2001cited by this paper
• Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.

  2000cited by this paper
• DNA damage-induced activation of p53 by the checkpoint kinase Chk2.

  2000cited by this paper
• The structure-based design of ATP-site directed protein kinase inhibitors.

  1999cited by this paper
• Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

  1999cited by this paper
• Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.

  1998cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Investigation into the Neuroprotective and Therapeutic Potential of Plant-Derived Chk2 Inhibitors

  2024cites this paper
• Unveiling the potential of Chinese herbs in combating cervical cancer: Understanding their mechanisms of action and herbal formulations

  2024cites this paper
• Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?

  2023cites this paper
• DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities

  2023cites this paper
• DNA damage response and repair in the development and treatment of brain tumors.

  2022cites this paper
• Nucleic Acid Sensing Pathways in DNA Repair Targeted Cancer Therapy

  2022cites this paper
• DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities

  2022cites this paper
• DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions

  2022cites this paper
• Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer

  2022cites this paper
• Evolving DNA repair synthetic lethality targets in cancer

  2022cites this paper
• Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma

  2022cites this paper
• Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and Its Implication in Cancer Therapy

  2021influential citation
• The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer.

  2021cites this paper
• Chemical and biological basis for development of novel radioprotective drugs for cancer therapy

  2021cites this paper
• Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer.

  2021cites this paper
• DNA Damage Repair Genes and Noncoding RNA in High-Grade Gliomas and Its Clinical Relevance

  2021cites this paper
• The promise of DNA damage response inhibitors for the treatment of glioblastoma

  2021cites this paper
• Natural podophyllotoxin analog 4DPG attenuates EMT and colorectal cancer progression via activation of checkpoint kinase 2

  2021cites this paper
• Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma

  2020cites this paper
• Ethyl 1H-indole-2-carboxylate

  2020cites this paper
• DNA damage checkpoint kinases in cancer

  2020cites this paper
• Divergent Synthesis and Evaluation of the in vitro Cytotoxicity Profiles of 3,4‐Ethylenedioxythiophenyl‐2‐propen‐1‐one Analogues

  2019cites this paper
• π‐Hole Interactions Involving Nitro Aromatic Ligands in Protein Structures

  2019cites this paper
• Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation

  2018cites this paper
• Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy

  2018cites this paper
• Chk2 deficiency alleviates irradiation-induced taste dysfunction by inhibiting p53-dependent apoptosis.

  2018cites this paper
• Assessment of the impact of deregulated signal transduction pathways on the radiotherapy response of non-small-cell lung cancer

  2018cites this paper
• Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.

  2018cites this paper
• Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors

  2018cites this paper
• Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates.

  2018cites this paper
• Translational research in radiation-induced DNA damage signaling and repair.

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• Directing the use of DDR kinase inhibitors in cancer treatment

  2017cites this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cites this paper
• ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

  2017cites this paper
• Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine

  2017cites this paper
• Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.

  2017cites this paper
• Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization

  2016cites this paper
• The Effect of Caffeine and chk2 Inhibitor on Doxorubicin-Induced Cellular Senescence in MCF-7 Cells

  2016cites this paper
• Targeting homologous recombination repair in cancer

  2016cites this paper
• Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisons

  2016cites this paper
• Azine-Hydrazone Tautomerism of Guanylhydrazones: Evidence for the Preference Toward the Azine Tautomer.

  2016cites this paper
• Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.

  2016cites this paper
• Prolonging Reproductive Life after Cancer: The Need for Fertoprotective Therapies.

  2016cites this paper
• Exploring the global animal biodiversity in the search for new drugs -marine invertebrates

  2016cites this paper
• Cancer TARGETases: DSB repair as a pharmacological target.

  2016cites this paper
• APRIN(PDS5B) et PALB2, deux protéines impliquées dans la réparation de l'ADN par recombinaison homologue et l'apparition de cancers

  2016influential citation
• Novel and Emerging Targeted Therapies of Colorectal Cancer.

  2015cites this paper
• The role of nucleotide excision repair factors and the Mre11 nuclease in nucleoside analogue sensitivity

  2015cites this paper
• miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth

  2015cites this paper
• Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells

  2015cites this paper
• Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

  2015cites this paper
• DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

  2015cites this paper
• The Role of chk2 in Response to DNA Damage in Cancer Cells

  2015cites this paper
• AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells*

  2015influential citation
• Kinase-independent role for CRAF-driving tumour radioresistance via CHK2

  2015cites this paper
• Inhibition of DNA Repair as a Therapeutic Target

  2014cites this paper
• Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures

  2014cites this paper
• Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

  2014cites this paper
• Novel Design Strategy for Checkpoint Kinase 2 Inhibitors Using Pharmacophore Modeling, Combinatorial Fusion, and Virtual Screening

  2014cites this paper
• Checkpoint kinase Chk2 controls renal Cyp27b1 expression, calcitriol formation, and calcium-phosphate metabolism

  2014cites this paper
• Development of Synthetic Lethality Anticancer Therapeutics

  2014cites this paper
• Role of CHK2 inhibitors in the cellular responses to ionizing radiation.

  2014cites this paper
• 4'-Demethyl-deoxypodophyllotoxin glucoside isolated from Podophyllum hexandrum exhibits potential anticancer activities by altering Chk-2 signaling pathway in MCF-7 breast cancer cells.

  2014cites this paper
• Structure-based design , discovery and development of checkpoint kinase inhibitors as potential anti-cancer therapies

  2014influential citation
• Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary

  2014cites this paper
• from Podophyllum hexandrum exhibits potential anticancer activities by altering Chk-2 signaling pathway in MCF-7 breast cancer cells

  2014cites this paper
• Novel Role of CHK2 in the Intrinsic and Extrinsic Apoptosis Pathway

  2014cites this paper
• Perspective: Opportunities in recalcitrant, rare and neglected tumors

  2013cites this paper
• Cancer Therapy : Preclinical Sensitization of Pancreatic Cancer to Chemoradiation by the Chk 1 Inhibitor MK 8776

  2013cites this paper
• Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

  2013cites this paper
• Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

  2013cites this paper
• Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

  2013cites this paper
• 3D-QSAR Study for Checkpoint Kinase 2 Inhibitors through Pharmacophore Hypotheses

  2013cites this paper
• Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.

  2013cites this paper
• Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

  2013cites this paper
• Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers

  2013cites this paper
• Radiation Induced DNA Damage, Repair and Therapeutics

  2013cites this paper
• Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2

  2013cites this paper
• Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine

  2013cites this paper
• Benzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein–ligand crystallography

  2012cites this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cites this paper
• DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

  2012influential citation
• Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.

  2012cites this paper
• Superaugmented Eccentric Distance Sum Connectivity Indices: Novel Highly Discriminating Topological Descriptors for QSAR/QSPR

  2012cites this paper
• Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.

  2012cites this paper
• CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute

  2012cites this paper
• A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe

  2011cites this paper
• Anticancer therapy with checkpoint inhibitors: what, where and when?

  2011cites this paper
• Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

  2011influential citation
• Current inhibitors of checkpoint kinase 2.

  2011cites this paper
• CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

  2011cites this paper
• Checkpoint kinase inhibitors: a patent review (2009 – 2010)

  2011cites this paper
• Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

  2011cites this paper
• X‐ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper‐dependent hydrophobic pocket

  2011cites this paper
• Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.

  2011cites this paper
• Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.

  2011cites this paper
• The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor

  2010cites this paper
• A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage.

  2010cites this paper
• Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.

  2010cites this paper